Statement of Beneficial Ownership (sc 13d)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. )*

Altimmune, Inc.

(Name of Issuer)

COMMON STOCK

(Title of Class of Securities)

02155H200

(CUSIP Number)

Attention: General Counsel

Venrock

3340 Hillview Avenue

Palo Alto, California 94304

Name, Address and Telephone Number of Person Authorized to

Receive Notices and Communications)

June 15, 2020

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. x

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule.13d-7 for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 02155H200

Page 2 of 24

1	NAMES OF REPORTING PERSONS: Venrock Healthcare Capital Partners II, L.P.
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS): (a) x¹ (b) ¨
3	SEC USE ONLY:
4	SOURCE OF FUNDS (SEE INSTRUCTIONS): OO
5	CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e): ¨
6	CITIZENSHIP OR PLACE OF ORGANIZATION: Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		7	SOLE VOTING POWER: 0
		8	SHARED VOTING POWER: 4,500,000²
		9	SOLE DISPOSITIVE POWER: 0
		10	SHARED DISPOSITIVE POWER: 4,500,000²
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON: 4,500,000²
12	CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS): ¨
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11): 20.8%³
14	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS): PN

CUSIP No. 02155H200

Page 3 of 24

Venrock Healthcare Capital Partners II, L.P., VHCP Co-Investment Holdings II, LLC, Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, VHCP Management II, LLC, VHCP Management III, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13D.

Consists of 1,189,350 shares owned by Venrock Healthcare Capital Partners II, L.P., 481,949 shares owned by VHCP Co-Investment Holdings II, LLC, 2,571,752 shares owned by Venrock Healthcare Capital Partners III, L.P. and 256,949 shares owned by VHCP Co-Investment Holdings III, LLC.

This percentage is calculated based on an estimated 21,611,698 shares of common stock outstanding as of the date hereof, which consists of 20,111,698 shares of common stock outstanding on May 29, 2020, as reported in the Issuer’s prospectus supplement filed with the Securities and Exchange Commission on June 1, 2020, plus 1,500,000 shares of common stock purchased by the Reporting Persons directly from the Issuer pursuant to an at-the-market offering on June 15, 2020.

CUSIP No. 02155H200

Page 4 of 24

1	NAMES OF REPORTING PERSONS: VHCP Co-Investment Holdings II, LLC
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS): (a) x¹ (b) ¨
3	SEC USE ONLY:
4	SOURCE OF FUNDS (SEE INSTRUCTIONS): OO
5	CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e): ¨
6	CITIZENSHIP OR PLACE OF ORGANIZATION: Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		7	SOLE VOTING POWER: 0
		8	SHARED VOTING POWER: 4,500,000²
		9	SOLE DISPOSITIVE POWER: 0
		10	SHARED DISPOSITIVE POWER: 4,500,000²
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON: 4,500,000²
12	CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS): ¨
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11): 20.8%³
14	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS): OO

CUSIP No. 02155H200

Page 5 of 24

CUSIP No. 02155H200

Page 6 of 24

1	NAMES OF REPORTING PERSONS: Venrock Healthcare Capital Partners III, L.P.
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS): (a) x¹ (b) ¨
3	SEC USE ONLY:
4	SOURCE OF FUNDS (SEE INSTRUCTIONS): OO
5	CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e): ¨
6	CITIZENSHIP OR PLACE OF ORGANIZATION: Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		7	SOLE VOTING POWER: 0
		8	SHARED VOTING POWER: 4,500,000²
		9	SOLE DISPOSITIVE POWER: 0
		10	SHARED DISPOSITIVE POWER: 4,500,000²
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON: 4,500,000²
12	CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS): ¨
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11): 20.8%³
14	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS): PN

CUSIP No. 02155H200

Page 7 of 24

CUSIP No. 02155H200

Page 8 of 24

1	NAMES OF REPORTING PERSONS: VHCP Co-Investment Holdings III, LLC
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS): (a) x¹ (b) ¨
3	SEC USE ONLY:
4	SOURCE OF FUNDS (SEE INSTRUCTIONS): OO
5	CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e): ¨
6	CITIZENSHIP OR PLACE OF ORGANIZATION: Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		7	SOLE VOTING POWER: 0
		8	SHARED VOTING POWER: 4,500,000²
		9	SOLE DISPOSITIVE POWER: 0
		10	SHARED DISPOSITIVE POWER: 4,500,000²
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON: 4,500,000²
12	CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS): ¨
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11): 20.8%³
14	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS): OO

CUSIP No. 02155H200

Page 9 of 24

CUSIP No. 02155H200

Page 10 of 24

1	NAMES OF REPORTING PERSONS: VHCP Management II, LLC
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS): (a) x¹ (b) ¨
3	SEC USE ONLY:
4	SOURCE OF FUNDS (SEE INSTRUCTIONS): OO
5	CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e): ¨
6	CITIZENSHIP OR PLACE OF ORGANIZATION: Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		7	SOLE VOTING POWER: 0
		8	SHARED VOTING POWER: 4,500,000²
		9	SOLE DISPOSITIVE POWER: 0
		10	SHARED DISPOSITIVE POWER: 4,500,000²
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON: 4,500,000²
12	CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS): ¨
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11): 20.8%³
14	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS): OO

CUSIP No. 02155H200

Page 11 of 24

CUSIP No. 02155H200

Page 12 of 24

1	NAMES OF REPORTING PERSONS: VHCP Management III, LLC
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS): (a) x¹ (b) ¨
3	SEC USE ONLY:
4	SOURCE OF FUNDS (SEE INSTRUCTIONS): OO
5	CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e): ¨
6	CITIZENSHIP OR PLACE OF ORGANIZATION: Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		7	SOLE VOTING POWER: 0
		8	SHARED VOTING POWER: 4,500,000²
		9	SOLE DISPOSITIVE POWER: 0
		10	SHARED DISPOSITIVE POWER: 4,500,000²
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON: 4,500,000²
12	CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS): ¨
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11): 20.8%³
14	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS): OO

CUSIP No. 02155H200

Page 13 of 24

CUSIP No. 02155H200

Page 14 of 24

1	NAMES OF REPORTING PERSONS: Shah, Nimish
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS): (a) x¹ (b) ¨
3	SEC USE ONLY:
4	SOURCE OF FUNDS (SEE INSTRUCTIONS): OO
5	CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e): ¨
6	CITIZENSHIP OR PLACE OF ORGANIZATION: United States
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		7	SOLE VOTING POWER: 0
		8	SHARED VOTING POWER: 4,500,000²
		9	SOLE DISPOSITIVE POWER: 0
		10	SHARED DISPOSITIVE POWER: 4,500,000²
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON: 4,500,000²
12	CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS): ¨
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11): 20.8%³
14	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS): IN

CUSIP No. 02155H200

Page 15 of 24

CUSIP No. 02155H200

Page 16 of 24

1	NAMES OF REPORTING PERSONS: Koh, Bong
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS): (a) x¹ (b) ¨
3	SEC USE ONLY:
4	SOURCE OF FUNDS (SEE INSTRUCTIONS): OO
5	CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e): ¨
6	CITIZENSHIP OR PLACE OF ORGANIZATION: United States
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		7	SOLE VOTING POWER: 0
		8	SHARED VOTING POWER: 4,500,000²
		9	SOLE DISPOSITIVE POWER: 0
		10	SHARED DISPOSITIVE POWER: 4,500,000²
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON: 4,500,000²
12	CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS): ¨
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11): 20.8%³
14	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS): IN

CUSIP No. 02155H200

Page 17 of 24

CUSIP No. 02155H200

Page 18 of 24

This Schedule 13D is being filed by the Venrock Entities (as defined below) and the Venrock GPs (as defined below) to report the acquisition of Common Stock, as described in Item 3 below.

ITEM 1. SECURITY AND ISSUER

The class of equity securities to which this statement relates is Common Stock, par value $0.0001 per share (the “Common Stock”), of Altimmune, Inc., a Delaware corporation (the “Issuer” or “Altimmune”). The principal executive offices of the Issuer are located at 910 Clopper Road, Suite 201A, Gaithersburg, Maryland 20878.

ITEM 2. IDENTITY AND BACKGROUND

(a)

This Schedule 13D is filed by Venrock Healthcare Capital Partners II, L.P. (“VHCP II”), VHCP Co-Investment Holdings II, LLC (“VHCP-Co II”), Venrock Healthcare Capital Partners III, L.P. (“VHCP III”) and VHCP Co-Investment Holdings III, LLC (“VHCP-Co III” and together with VHCP II, VHCP-Co II and VHCP III, the “Venrock Entities”). VHCP Management II, LLC (“VHCPM II”) is the general partner of VHCP II and the manager of VHCP-Co II, and VHCP Management III, LLC (“VHCPM III” and together with VHCPM II, the “Venrock GPs”) is the general partner of VHCP III and the manager of VHCP-Co III. Nimish Shah (“Shah”) and Bong Koh (“Koh”) are the voting members of the Venrock GPs.

(b)	The address of the principal place of business of each of the Venrock Entities, Venrock GPs, Shah and Koh is 7 Bryant Park, 23^rd Floor, New York, NY 10018.

(c)	The principal business of each of the Venrock Entities, Venrock GPs, Shah and Koh is a venture capital investment business.

(d)	During the last five years, none of the Venrock Entities, Venrock GPs, Shah or Koh has been convicted in any criminal proceeding (excluding traffic violations or similar misdemeanors).

(e)

During the last five years, none of the Venrock Entities, Venrock GPs, Shah or Koh has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction resulting in such Venrock Entity, Venrock GP, Shah or Koh being subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

(f)	Each of the Venrock Entities is a Delaware limited partnership and each of the Venrock GPs is a Delaware limited liability company. Shah and Koh are each United States citizens.

ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION

As of the date hereof, the Venrock Entities may be deemed to beneficially own an aggregate of 4,500,000 shares of Common Stock, all of which were acquired between May 20, 2020 and June 15, 2020, as described in greater detail in Item 5. Of these shares, an aggregate of 3,000,000 shares were acquired in open market transactions for an aggregate purchase price of $22.0 million and an aggregate of 1,500,000 shares were acquired directly from the Issuer pursuant to an at the market (“ATM”) offering program for an aggregate purchase price of $11.3 million. The funds used by the Venrock Entities to acquire the securities described herein were obtained from capital contributions from their respective partners.

CUSIP No. 02155H200

Page 19 of 24

ITEM 4. PURPOSE OF TRANSACTION

The Venrock Entities acquired the securities for investment purposes with the aim of increasing the value of its investments and the Issuer.

Subject to applicable legal requirements, one or more of the Reporting Persons may purchase or sell additional securities of the Issuer from time to time in open market or private transactions, depending on their evaluation of the Issuer’s business, prospects and financial condition, the market for the Issuer’s securities, other developments concerning the Issuer, the reaction of the Issuer to the Reporting Persons’ ownership of the Issuer’s securities, other opportunities available to the Reporting Persons, and general economic, money market and stock market conditions. In addition, depending upon the factors referred to above, the Reporting Persons may dispose of all or a portion of their securities of the Issuer at any time. Each of the Reporting Persons reserves the right to increase or decrease its holdings on such terms and at such times as each may decide.

Other than as described above, as of the date of this Schedule 13D, none of the Reporting Persons has any present plans which relate to or would result in:

(a)

the acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer;

(b)

an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries;

(c)

a sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries;

(d)

any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board;

(e)

any material change in the present capitalization or dividend policy of the Issuer;

(f)

any other material change in the Issuer’s business or corporate structure including but not limited to, if the Issuer is a registered closed-end investment company, any plans or proposals to make any changes in its investment policy for which a vote is required by Section 13 of the Investment Company Act of 1940;

(g)

changes in the Issuer’s charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Issuer by any person;

(h)

causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association;

(i)

a class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Act; or

(j)

any action similar to any of those enumerated above.

CUSIP No. 02155H200

Page 20 of 24

ITEM 5. INTEREST IN SECURITIES OF THE ISSUER

The Reporting Persons are members of a group for purposes of this Schedule 13D.

(a) As of the date hereof, the Venrock Entities own the following shares:

Reporting Persons	Shares Held Directly		Sole Voting Power		Shared Voting Power (1)		Sole Dispositive Power		Shared Dispositive Power (1)		Beneficial Ownership		Percentage of Class (2)
VHCP II		1,189,350		—		4,500,000		—		4,500,000		4,500,000		20.8	%
VHCP Co-II		481,949		—		4,500,000		—		4,500,000		4,500,000		20.8	%
VHCP III		2,571,752		—		4,500,000		—		4,500,000		4,500,000		20.8	%
VHCP Co-III		256,949		—		4,500,000		—		4,500,000		4,500,000		20.8	%
VHCPM II		—		—		4,500,000		—		4,500,000		4,500,000		20.8	%
VHCPM III		—		—		4,500,000		—		4,500,000		4,500,000		20.8	%
Shah		—		—		4,500,000		—		4,500,000		4,500,000		20.8	%
Koh		—		—		4,500,000		—		4,500,000		4,500,000		20.8	%

(1)

Shah and Koh are the voting members of VHCPM II (the general partner of VHCP II and manager of VHCP-Co II) and VHCPM III (the general partner of VHCP III and manager of VHCP-Co III). The Venrock GPs, Shah and Koh own no securities of the Issuer directly. Shah and Koh share voting and investment control over the securities owned by the Venrock Entities and may be deemed to beneficially own the securities held by those entities. As general partners of the Venrock Entities, the Venrock GPs may be deemed to beneficially own the securities held by those entities.

(2)

(b)

Each of the Reporting Persons has sole power to vote or to direct the vote of no shares of Common Stock, sole power to dispose or to direct the disposition of no shares of Common Stock, shared power to vote or to direct the vote of 4,500,000 shares of Common Stock and shared power to dispose or to direct the disposition of 4,500,000 shares of Common Stock.

CUSIP No. 02155H200

Page 21 of 24

(c)

The shares of Common Stock beneficially owned by the Reporting Persons were acquired as follows:

VHCP II

Date of Transaction	Type of Purchase	Number of Shares Acquired		Weighted Average Price Per Share		Low Price		High Price
20-May-20	Open market		396,450	$	6.23	$	5.98	$	6.44
21-May-20	Open market		12,386	$	6.11	$	6.11	$	6.11
22-May-20	Open market		39,513	$	6.71	$	6.71	$	6.71
26-May-20	Open market		185,010	$	9.34	$	8.40	$	10.00
27-May-20	Open market		106,291	$	7.71	$	6.63	$	8.05
28-May-20	Open market		53,250	$	8.72	$	7.61	$	9.00
15-Jun-20	ATM		396,450	$	7.54	$	7.54	$	7.54

VHCP Co-II

Date of Transaction	Type of Purchase	Number of Shares Acquired		Weighted Average Price Per Share		Low Price		High Price
20-May-20	Open market		160,650	$	6.23	$	5.98	$	6.44
21-May-20	Open market		5,019	$	6.11	$	6.11	$	6.11
22-May-20	Open market		16,011	$	6.71	$	6.71	$	6.71
26-May-20	Open market		74,970	$	9.34	$	8.40	$	10.00
27-May-20	Open market		43,071	$	7.71	$	6.63	$	8.05
28-May-20	Open market		21,578	$	8.72	$	7.61	$	9.00
15-Jun-20	ATM		160,650	$	7.54	$	7.54	$	7.54

VHCP III

Date of Transaction	Type of Purchase	Number of Shares Acquired		Weighted Average Price Per Share		Low Price		High Price
20-May-20	Open market		857,250	$	6.23	$	5.98	$	6.44
21-May-20	Open market		26,783	$	6.11	$	6.11	$	6.11
22-May-20	Open market		85,440	$	6.71	$	6.71	$	6.71
26-May-20	Open market		400,050	$	9.34	$	8.40	$	10.00
27-May-20	Open market		229,837	$	7.71	$	6.63	$	8.05
28-May-20	Open market		115,142	$	8.72	$	7.61	$	9.00
15-Jun-20	ATM		857,250	$	7.54	$	7.54	$	7.54

CUSIP No. 02155H200

Page 22 of 24

VHCP Co-III

Date of Transaction	Type of Purchase	Number of Shares Acquired		Weighted Average Price Per Share		Low Price		High Price
20-May-20	Open market		85,650	$	6.23	$	5.98	$	6.44
21-May-20	Open market		2,676	$	6.11	$	6.11	$	6.11
22-May-20	Open market		8,536	$	6.71	$	6.71	$	6.71
26-May-20	Open market		39,970	$	9.34	$	8.40	$	10.00
27-May-20	Open market		22,963	$	7.71	$	6.63	$	8.05
28-May-20	Open market		11,504	$	8.72	$	7.61	$	9.00
15-Jun-20	ATM		85,650	$	7.54	$	7.54	$	7.54

Except as reported herein, the Reporting Persons have not engaged in any transactions involving the securities of the Issuer in the last 60 days.

(d)

No other person is known by the Reporting Persons to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, Common Stock beneficially owned by the Reporting Persons.

(e)

Not applicable.

ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER

To the best of the Reporting Persons’ knowledge, there are no contracts, arrangements, understandings or relationships (legal or otherwise) among the persons named in Item 2 and between such persons and any person with respect to any securities of the Issuer.

ITEM 7. MATERIAL TO BE FILED AS EXHIBITS

	A.	Agreement regarding filing of joint Schedule 13D.

	B.	Power of Attorney for Bong Koh (incorporated by reference to Exhibit B to Schedule 13D filed with the Securities and Exchange Commission on June 1, 2020).

	C.	Power of Attorney for Nimish Shah (incorporated by reference to Exhibit C to Schedule 13D filed with the Securities and Exchange Commission on June 1, 2020).

CUSIP No. 02155H200

Page 23 of 24

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: June 25, 2020

Venrock Healthcare Capital Partners II, L.P.			Venrock Healthcare Capital Partners III, L.P.

By:	VHCP Management II, LLC		By:	VHCP Management III, LLC
Its:	General Partner		Its:	General Partner

By:	/s/ David L. Stepp		By:	/s/ David L. Stepp
	Name:	David L. Stepp		Name:	David L. Stepp
	Its:	Authorized Signatory		Its:	Authorized Signatory

VHCP Co-Investment Holdings II, LLC			VHCP Co-Investment Holdings III, LLC

By:	VHCP Management II, LLC		By:	VHCP Management III, LLC
Its:	Manager		Its:	Manager

By:	/s/ David L. Stepp		By:	/s/ David L. Stepp
	Name:	David L. Stepp		Name:	David L. Stepp
	Its:	Authorized Signatory		Its:	Authorized Signatory

VHCP Management II, LLC			VHCP Management III, LLC

By:	/s/ David L. Stepp		By:	/s/ David L. Stepp
	Name:	David L. Stepp		Name:	David L. Stepp
	Its:	Authorized Signatory		Its:	Authorized Signatory

Nimish Shah			Bong Koh

By:	/s/ David L. Stepp		By:	/s/ David L. Stepp
	David L. Stepp, as attorney-in-fact			David L. Stepp, as attorney-in-fact

The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative (other than an executive officer or general partner of the filing person), evidence of the representative’s authority to sign on behalf of such person shall be filed with the statement: provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)

CUSIP No. 02155H200

Page 24 of 24

EXHIBIT A

AGREEMENT

Pursuant to Rule 13d-1(k)(1) promulgated pursuant to the Securities Exchange Act of 1934, as amended, the undersigned agree that the attached Schedule 13D is being filed on behalf of each of the undersigned.

Dated: June 25, 2020

Venrock Healthcare Capital Partners II, L.P.			Venrock Healthcare Capital Partners III, L.P.

By:	VHCP Management II, LLC		By:	VHCP Management III, LLC
Its:	General Partner		Its:	General Partner

By:	/s/ David L. Stepp		By:	/s/ David L. Stepp
	Name:	David L. Stepp		Name:	David L. Stepp
	Its:	Authorized Signatory		Its:	Authorized Signatory

VHCP Co-Investment Holdings II, LLC			VHCP Co-Investment Holdings III, LLC

By:	VHCP Management II, LLC		By:	VHCP Management III, LLC
Its:	Manager		Its:	Manager

By:	/s/ David L. Stepp		By:	/s/ David L. Stepp
	Name:	David L. Stepp		Name:	David L. Stepp
	Its:	Authorized Signatory		Its:	Authorized Signatory

VHCP Management II, LLC			VHCP Management III, LLC

By:	/s/ David L. Stepp		By:	/s/ David L. Stepp
	Name:	David L. Stepp		Name:	David L. Stepp
	Its:	Authorized Signatory		Its:	Authorized Signatory

Nimish Shah			Bong Koh

By:	/s/ David L. Stepp		By:	/s/ David L. Stepp
	David L. Stepp, as attorney-in-fact			David L. Stepp, as attorney-in-fact